GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine–induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, GLP-1RAs have demonstrated considerable therapeutic promise in animal models of both PD and AD.427–429”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to its effects on metabolic regulation, GLP-1, when synthesized within the brain, exhibits neuroprotective properties.397,427,431”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 10×
“These and other actions are mediated through the G protein-coupled GLP-1R, and Ex-4 has demonstrated therapeutic value in T2DM (7).”
BackgroundMethodInfluentialDiabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“GLP-1R mRNA occurs widely throughout the brains of rodents (9) and humans (6,7,10), and both GLP-1 and Ex-4 can readily enter the brain (11) to modify feeding and satiety (12).”
BackgroundJavitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263 · cited 2×
“Administration of MPTP in mice induces a consistent dopaminergic cell loss that parallels many aspects of PD (16,20).”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 3×
“Although T2DM now occurs more often in the young, the incidence rises dramatically with age, along with that of many of other conditions, including acute and chronic neurologic disorders, exemplified by stroke (2), Parkinson’s disease (PD) and Alzheimer’s disease (AD) (3,4), which, like T2DM, were once considered rela…”
BackgroundD'Mello, S. R., Galli, C., Ciotti, T., & Calissano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10989 · Cited by 892 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“These neurotrophic/protective actions are in accordance with previous findings establishing that GLP-1R stimulation protects hippocampal neurons from amyloid- peptide–, Fe2 -, and glutamate-induced toxicity (15,32,33).”
BackgroundResultInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Mattson, M. P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00275.x · Cited by 751 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
BackgroundSelf-citationCell death in the nervous system
Bredesen, D. E., Rao, R. V., & Mehlen, P. (2006) · Nature · doi:10.1038/nature05293 · Cited by 636 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
Background
Research works printed but not linked: 2
- R Sicree, J Shaw, P Zimmet Diabetes Atlas, ed D Gan (International Diabetes Federation, 3rd Ed, Brussels), pp. 15–103 (2006).
- 10.1210/endo.140.3.6550 · doi:10.1210/endo.140.3.6550 · Paper page
Cited by
Items 201–300 of 629
Yang, D. W., Nakajo, Y., Iihara, K., Kataoka, H., & Yanamoto, H. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.015 · Cited by 63
“Exendin-4 (Ex-4), a long-acting analog of GLP-1 (a GLP-R agonist), developed for intravenous treatment of type II diabetes mellitus (DM-2), demonstrated a neuroprotective property in vivo after cerebro-ventricular administration (Li et al., 2009).”
Guerrero-Hreins, E., Goldstone, A. P., Brown, R. M., & Sumithran, P. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110303 · Cited by 62
GLP-1 programs the neurovascular landscape
Chen, B., Yu, X., HORVATH-DIANO, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.003 · Cited by 62
Liu, Q., Li, N., Yuan, Y., Lu, H., Wu, X., Zhou, C., He, M., Su, H., Zhang, M., Wang, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201150j · Cited by 62
Self-citationSeppa, K., Toots, M., Reimets, R., Jagomäe, T., Koppel, T., Pallase, M., Hasselholt, S., Krogsbæk Mikkelsen, M., Randel Nyengaard, J., Vasar, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52295-2 · Cited by 53
Lin, T.-K., Lin, K.-J., Lin, H.-Y., Lin, K.-L., Lan, M.-Y., Wang, P.-W., Wang, T.-J., Wang, F.-S., Tsai, P.-C., Liou, C.-W., et al. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.697440 · Cited by 49
Cao, B., Zhang, Y., Chen, J., Wu, P., Dong, Y., & Wang, Y. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00879-1 · Cited by 62
“Importantly, most GLP-1 analogs can enter the central nervous system through the blood-brain barrier, where they exert a variety of physiological effects on their receptors (Chen et al. 2018; Hunter and Hölscher 2012; Li et al. 2009).”
BackgroundSelf-citationMarlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
Kuroki, T., Tanaka, R., Shimada, Y., Yamashiro, K., Ueno, Y., Shimura, H., Urabe, T., & Hattori, N. (2016) · Stroke · doi:10.1161/strokeaha.116.012934 · Cited by 60
“therapeutic agents for various neurodegenerative disorders, including stroke.(20,21) Several previous studies, including”
BackgroundResveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota
Chung, J. Y., Jeong, J., & Song, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.588044 · Cited by 60
“, 2018) in neurodegenerative diseases, such as Alzheimer’s disease (Holscher, 2014), Parkinson’s disease (Li et al., 2009), and stroke (Darsalia et al.”
BackgroundZhang, L., Li, C., Zhang, Z., Zhang, Z., Jin, Q., Li, L., & Hölscher, C. (2022) · Parkinson s Disease · doi:10.1155/2022/1428817 · Cited by 60
“Te frst GLP-1 mimetic exendin-4 (Exe-natide, Byetta, and Bydureon), brought to the market to treat T2DM, showed a therapeutic efect in preclinical tests of PD [33, 37, 38].”
Oxidative stress–dependent phosphorylation activates ZNRF1 to induce neuronal/axonal degeneration
Wakatsuki, S., Furuno, A., Ohshima, M., & Araki, T. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201506102 · Cited by 59
“…types of neurons, we performed a parallel series of studies on SHSY5Y neuroblastoma cells and ventral mesencephalic neuron cultures, which are known to be rich in dopaminergic neurons (Li et al., 2009), and obtained similar results to those from primary cultured cortical neurons (unpublished data).”
ResultWiberg, S. C., Hassager, C., Schmidt, H., Thomsen, J. H., Frydland, M. S., Lindholm, M. G., Høfsten, D. E., Engstrøm, T., Køber, L., Møller, J. E., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.024088 · Cited by 59
Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy
Bu, L.-L., Liu, Y., Shen, Y., Fan, Y., Yu, W., Jiang, D., Tang, Y., Yang, Y., Wu, P., Zuo, C., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01018-5 · Cited by 59
Elbassuoni, E. A., & Ahmed, R. F. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104583 · Cited by 54
Kim, S., Jeong, J., Jung, H.-S., Kim, B., Kim, Y.-E., Lim, D.-S., Kim, S.-D., & Song, Y. S. (2017) · Experimental Neurobiology · doi:10.5607/en.2017.26.4.227 · Cited by 57
“It has been demonstrated that GLP-1R stimulation conferred neuroprotection in stroke and Parkinsonism [9, 10].”
BackgroundInfluentialYu, H., Sun, T., He, X., Wang, Z., Zhao, K., An, J., Wen, L., Li, J., Li, W., & Feng, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.0325 · Cited by 57
“The natural GLP-1 mimetic exendin-4 has neuroprotective roles in several PD animal models [154, 155].”
BackgroundVentorp, F., Bay-Richter, C., Nagendra, A. S., Janelidze, S., Matsson, V. S., Lipton, J., Nordström, U., Westrin, Å., Brundin, P., & Brundin, L. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-171068 · Cited by 56
“In addition, it is known that exendin-4 has neuroprotective properties, as it protects dopaminergic neurons in Parkinson’s disease (PD) rodent models [7, 8] and preserves synaptic plasticity in the hippocampus in animal models of Alzheimer’s disease (AD) [9–12].”
BackgroundDiabetes: Risk factor and translational therapeutic implications for Alzheimer's disease
Cummings, J., Ortiz, A., Castellino, J., & Kinney, J. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15619 · Cited by 48
“GLP-1 reduces oxidative stress, is involved in autophagy regulation and exhibits anti-inflammatory protective functions (e.g., anti-inflammatory signalling) in the CNS (Li et al., 2009).”
BackgroundInfluentialGlucagon‐like peptide‐1 protects synaptic and learning functions from neuroinflammation in rodents
Iwai, T., Sawabe, T., Tanimitsu, K., Suzuki, M., Sasaki‐Hamada, S., & Oka, J. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23335 · Cited by 49
“The concentration of GLP-1 (7–36) amide was based on previous studies in which maximal responses were obtained at 10–100 nM (G€oke et al., 1989; Perry et al., 2003; Li et al., 2009; Amato et al., 2010).”
BackgroundMethodInfluentialFan, Y., Liu, K., Wang, Q., Ruan, Y., Zhang, Y., & Ye, W. (2014) · PubMed Central · Cited by 55
Hölscher, C. (2014) · PubMed · Cited by 55
Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson’s Disease
Aksoy, D., Solmaz, V., Çavuşoğlu, T., Meral, A., Ateş, U., & Erbaş, O. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.05.002 · Cited by 55
Hakon, J., Ruscher, K., Romner, B., & Tomasevic, G. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120074 · Cited by 52
Foltynie, T., & Aviles-Olmos, I. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.005 · Cited by 49
“In neuronal cultures, 50% GLP-1 receptor occupancy is achieved with 14 nm exendin 4 [11], whereas complete protection against toxicity in vitro is achieved with 100 nm exendin 4 [33].”
BackgroundResultInfluentialThe pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
Zhang, L., Zhang, W., & Tian, X. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2021.1924707 · Cited by 54
“In ventral mesencephalic neuronal cultures that have a large content of DAergic neurons, both GLP-1 and Ex-4 rescued the remarkable decreased TH-positive cells induced by 6-OHDA, moreover, Ex-4 induced a 60% increase in TH-positive cells in the absence of 6-OHDA group [12].”
BackgroundProtection of Trigonelline on Experimental Diabetic Peripheral Neuropathy
Zhou, J., & Zhou, S.-W. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/164219 · Cited by 54
Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.048 · Cited by 47
“Studies using in vitro cultured cells have demonstrated that pretreating cells with GLP-1R agonists can protect them against cell death caused by amyloid beta (Ab) plaque accumulation, a biomarker for Alzheimer's disease (AD) (Perry et al., 2003; Li et al., 2009; McClean and Holscher, 2014; Cai et al., 2014).”
BackgroundLi, Y., Glotfelty, E. J., Karlsson, T., Fortuno, L. V., Harvey, B. K., & Greig, N. H. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15521 · Cited by 47
“…have previously demonstrated efficacy in reversing dopaminergic cell death in animal models of PD (Chen et al., 2018; Glotfelty et al., 2020; Li et al., 2009; Salcedo et al., 2012) and recently have shown benefits in a human PD clinical trial (Athauda et al., 2017), with further ones…”
BackgroundMethodInfluentialSelf-citationCherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Lima, M. M. S., Targa, A., Noseda, A. C. D., Rodrigues, L. S., Delattre, A. M., dos Santos, F. V., Fortes, M., Maturana, M. J., & Ferraz, A. C. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660155 · Cited by 53
“Activation of GLP-1 by an agonist, such as exedine-4, is reported to prevent the death of dopaminergic neurons in the 6-OHDA and lipopolysaccharide models of PD [140, 141].”
BackgroundTherapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Yang, X., Feng, P., Ji, R., Ren, Y., Wei, W., & Hölscher, C. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2079492 · Cited by 50
“analogs showed neuroprotective effects against insults that modeled PD, which were blocked by a GLP-1R antagonist and absent in cells from GLP-1R KO mice [108].”
BackgroundPorter, D., Faivre, É., Flatt, P. R., Hölscher, C., & Gault, V. A. (2012) · Peptides · doi:10.1016/j.peptides.2012.03.014 · Cited by 53
Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952011 · Cited by 51
“reported no significant change in body temperature when measured before and after treatment with exendin-4.(18) We did not identify any GLP-1RA study of AIS which varied temperature between groups.”
BackgroundAnimal Venom Peptides as a Treasure Trove for New Therapeutics Against Neurodegenerative Disorders
Yang, X., Wang, Y., Wu, C., & Ling, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181031122438 · Cited by 51
Self-citationExendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson′s disease
Yu, H., Sun, T., Wang, Z., Li, H., Xu, D., An, J., Wen, L.-L., Li, J., Li, W., & Feng, J. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.360242 · Cited by 51
“Beyond their normal physiological function, GLP-1Ras have been demonstrated to be neuroprotective in the context of many neurological diseases (Li et al., 2009).”
BackgroundNeuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model
Zhang, Y., Chen, Y., Li, L., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.021 · Cited by 51
“MPTP is a widely used chemical to induce a Parkinson-like state in animals for drug discovery (Kim et al., 2009; Kopin & Markey, 1988; Li et al., 2009; Nakamura & Vincent, 1986).”
Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway
Wang, M., Huang, Y., Zhang, G.-P., Mao, L., Xia, Y., Mei, Y.-W., & Hu, B. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.025 · Cited by 51
“Whether Ex-4 can protect neurons against brain ischemia warrants further study, but it has been confirmed that Ex-4 treatment reduces infarct size and improves outcome in MCAO (Li et al., 2009).”
BackgroundZhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0148827 · Cited by 50
“found that intracerebral administration of exendin-4 induced neuroprotection and locomotor activity after stroke in the rat, and showed this neuroprotective effect was mediated by GLP-1R in GLP-1R knockout mice [4].”
BackgroundIncretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Glotfelty, E. J., Delgado, T. E., Tovar-y-Romo, L. B., Luo, Y., Hoffer, B. J., Olson, L., Karlsson, T. E., Mattson, M. P., Harvey, B. K., Tweedie, D., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00003 · Cited by 48
Self-citationLuciani, P., Deledda, C., Benvenuti, S., Cellai, I., Squecco, R., Monici, M., Cialdai, F., Luciani, G., Danza, G., Stefano, C. D., et al. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0398-3 · Cited by 50
“Another study demonstrated that the administration of exendin-4 reduces brain damage and improves functional outcome in a transient middle cerebral artery occlusion stroke model [24].”
BackgroundAgrawal, R., Zhuang, Y., Cummings, B. P., Stanhope, K. L., Graham, J. L., Havel, P. J., & Gómez‐Pinilla, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.007 · Cited by 49
“GLP-1 also acts as a growth factor in the brain [20] and has been shown to protect neurons against various insults including Alzheimer's and Parkinson's diseases [21–23].”
Bader, M., Li, Y., Tweedie, D., Shlobin, N. A., Bernstein, A., Rubovitch, V., Tovar-y-Romo, L. B., DiMarchi, R. D., Hoffer, B. J., Greig, N. H., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00356 · Cited by 48
Self-citationA red light-controlled probiotic bio-system for in-situ gut-brain axis regulation
Zhang, X., Pang, G., Sun, T., Liu, X., Pan, H., Zhang, Y., Liu, J., Chang, J. K., Wang, H., & Liu, D. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122005 · Cited by 49
Gad, E. S., Zaitone, S. A., & Moustafa, Y. M. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0242 · Cited by 48
Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease
Chung, S. J., Jeon, S., Yoo, H. S., Kim, G., Oh, J. S., Kim, J. S., Evans, A. C., Sohn, Y. H., & Lee, P. H. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.08.023 · Cited by 43
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2019.10.008 · Cited by 44
Diabetes mellitus and Parkinson’s disease: dangerous liaisons between insulin and dopamine
Colosimo, C., Iuliis, A. D., Montinaro, E., Fatati, G., & Plebani, M. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320965 · Cited by 47
McGovern, S. F. J., Hunter, K., & Hölscher, C. (2012) · Brain Research · doi:10.1016/j.brainres.2012.07.029 · Cited by 47
Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
Christensen, M., & Knop, F. K. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0102-x · Cited by 47
“Finally, GLP-1 has been associated with improved learning and displayed neuroprotective effects in rodents [16, 17].”
BackgroundRebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R., & Fedele, E. (2018) · BioFactors · doi:10.1002/biof.1406 · Cited by 46
“Similar results on histological, neurochemical, and behavioral analysis were obtained with GLP-1R agonists in a different rodent model of PD [18].”
The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Menozzi, E., Schapira, A. H. V., & Borghammer, P. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70029 · Cited by 46
“86 For instance, in MPTP mouse models, treatment with exendin-4, a long-acting GLP-1RA, prevented dopaminergic neurons degeneration and motor impairment, pre-served dopamine levels, 124 and reduced microglia activation and in fl ammation.”
GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential
Moaket, O. S., Obaid, S. E., Obaid, F. E., Shakeeb, Y. A., Elsharief, S. M., Tania, A., Darwish, R., Butler, A. E., & Moin, A. S. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110743 · Cited by 46
Lawrence, E. C. N., Guo, M., Schwartz, T. D., Wu, J. J., Lu, J., Nikonov, S. S., Sterling, J. K., & Cui, Q. N. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1156829 · Cited by 45
“Through this anti-inflammatory effect, GLP-1R agonists are protective in several in vitro and animal models of neurodegeneration (Bertilsson et al., 2008; Harkavyi et al., 2008; Kim et al., 2009; Li et al., 2009; Erbil et al., 2019).”
BackgroundHan, L., Hölscher, C., Xue, G.-F., Li, G., & Li, D. (2016) · NeuroReport · doi:10.1097/wnr.0000000000000490 · Cited by 43
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Endocrine · doi:10.1007/s12020-014-0373-0 · Cited by 44
“Experimental data indicated that GLP-1 may exert actions in the brain by influencing neuronal health, cognition and neuroinflammation, thus resulting in mediation of feeding behavior and increased energy expenditure [49, 50].”
BackgroundUrkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 45
“The PI3K/Akt/mTOR pathway activation [67] is thought to mediate the GLP-1’s anti-apoptotic [70,71] and neurotrophic potential [72–74].”
Pang, S., Ren, Z., Ding, H., & Chan, P. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01265 · Cited by 44
Darsalia, V., Klein, T., Nyström, T., & Patrone, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.022 · Cited by 43
“at stroke time [stroke was induced by middle cerebral artery occlusion (MCAO)] (Li et al., 2009).”
MethodPotentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus
Groeneveld, O. N., Kappelle, L. J., & Biessels, G. J. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12420 · Cited by 43
Darsalia, V., Larsson, M., Nathanson, D., Klein, T., Nyström, T., & Patrone, C. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.17 · Cited by 44
CaMKK2 is inactivated by cAMP-PKA signaling and 14-3-3 adaptor proteins
Langendorf, C. G., O’Brien, M. T., Ngoei, K. R. W., McAloon, L. M., Dhagat, U., Hoque, A., Ling, N. X. Y., Dite, T. A., Galić, S., Loh, K., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013756 · Cited by 44
“Therefore, we examined the effect of the GLP-1 receptor agonist liraglutide on CaMKK2 activity in SHSY5Y neuroblastoma cells that endogenously express the GLP1 receptor (19).”
BackgroundBrundin, P., Barker, R. A., Conn, P. J., Dawson, T. M., Kieburtz, K. D., Lees, A. J., Schwarzschild, M. A., Tanner, C. M., Isaacs, T., Duffen, J., et al. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-139000 · Cited by 43
Tamargo, I. A., Bader, M., Li, Y., Yu, S.-J., Wang, Y., Talbot, K., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.005 · Cited by 42
Self-citationBeyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 44
Yin, F., Liu, J., Zheng, X., & Guo, L. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.28 · Cited by 43
Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice
Zhang, H., Meng, J., Zhou, S., Liu, Y., Qu, D., Wang, L., Li, X., Wang, N., Luo, X., & Ma, X. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9854-1 · Cited by 43
Tsai, Y.-R., Chang, C.-F., Lai, J.-H., Wu, J. C.-C., Chen, Y., Kang, S.-J., Hoffer, B. J., Tweedie, D., Luo, W., Greig, N. H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103252 · Cited by 43
“Notably, we have established the vulnerability of this and related cellular systems to oxidative and inflammatory stress and their mitigation in extensive prior studies [28,29,52,57].”
BackgroundSelf-citationThe gut–brain axis in early Parkinson’s disease: from prodrome to prevention
Oliver, P. J., Civitelli, L., & Hu, M. T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13138-5 · Cited by 42
Olukorode, J., Orimoloye, D. A., Nwachukwu, N. O., ONWUZO, C. N., Oloyede, P. O., Fayemi, T., Odunaike, O. S., Ayobami-Ojo, P. S., Divine, N., Alo, D. J., et al. (2024) · Cureus · doi:10.7759/cureus.72080 · Cited by 42
Hansen, H. H., Fabricius, K., Barkholt, P., Mikkelsen, J. D., Jelsing, J., Pyke, C., Knudsen, L. B., & Vrang, N. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.038 · Cited by 42
“On the basis of these reported findings, it may therefore also be speculated that VTA, rather than SNc, dopaminergic neurons were responsive to exendin-4 and GLP-1-induced neuroprotection in a study on 6-OHDA toxicity in rodent mesencephalic primary cell cultures (Li et al., 2009).”
BackgroundResultInfluentialMalik, F., & Li, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15446 · Cited by 41
GLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 42
“Similarly, Li and colleagues found that exendin-4 administration protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function [41].”
BackgroundYu, Y.-W., Hsieh, T.-H., Chen, K.-Y., Wu, J. C.-C., Hoffer, B. J., Greig, N. H., Li, Y., Lai, J.-H., Chang, C.-F., Lin, J.-W., et al. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4229 · Cited by 39
“The therapeutic effect of Ex-4 was mediated by GLP-1 receptor (GLP-1R) activation, because it can be blocked by the selective GLP-1R antagonist Exendin (9–39) and was ineffective in GLP-1R knockout mice.(60,61) GIP, like GLP-1, has a short half-life (approximately 7.”
BackgroundMethodSelf-citationThe promise of GLP-1 receptor agonists for neurodegenerative diseases
Athauda, D. S., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194745 · Cited by 43
“GLP-1RAs show robust neuroprotection in ischemic stroke models, reducing infarct size and enhancing recovery when given both before and after insult (144, 195).”
Self-citationLi, H., Jia, Z., Li, G., Zhao, X.-Z., Sun, P., Wang, J., Fan, Z., & Lv, G. (2015) · PubMed · Cited by 40
Parkinson’s disease: an update on pathogenesis and treatment
Foltynie, T., & Kahan, J. (2013) · Journal of Neurology · doi:10.1007/s00415-013-6915-1 · Cited by 40
“Parallel links between PD and diabetes pathogenesis are intriguing [65], and this group of drugs has been shown to have neurotrophic properties in vitro [66], as well as neuroprotective and neuro-restorative effects in a range of animal models [67, 68], accompanied by encouraging preliminary data in patients with PD […”
ResultManagement of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial
Bladin, C., Cheung, N. W., Dewey, H. M., Churilov, L. P., Middleton, S., Thijs, V., Ekinci, E. I., Levi, C. R., Lindley, R. I., Donnan, G. A., et al. (2023) · Stroke · doi:10.1161/strokeaha.123.044568 · Cited by 40
Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease
Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Lin, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.038 · Cited by 39
“Furthermore, two previous studies showed good protection of MPTP treated mice using the GLP-1 agonist exendin-4 (Kim et al., 2009; Li et al., 2009).”
BackgroundSelf-citationKamal, M. A., Priyamvada, S., Anbazhagan, A. N., Jabir, N. R., Tabrez, S. S. M., & Greig, N. H. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660137 · Cited by 39
Self-citationHuang, J., Liu, Y., Cheng, L., Li, J., Zhang, T., Zhao, G., & Zhang, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173581 · Cited by 36
Rahman, M. H., Jha, M. K., & Suk, K. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151204001234 · Cited by 39
Li, L., Zhang, L.-Y., Jin, Q.-Q., & Hölscher, C. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.303045 · Cited by 38
Jia, X.-T., Ye-Tian, Yuanli, Zhang, G., Liu, Z., Di, Z., Ying, X., Yan, F., Song, E., Qi, J., et al. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.03.016 · Cited by 38
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
Jung, Y. J., Tweedie, D., Scerba, M. T., Kim, D. S., Palmas, M. F., Pisanu, A., Carta, A. R., & Greig, N. H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.656921 · Cited by 38
Self-citationSaleh, R. A., Eissa, T. F., Abdallah, D. M., Saad, M. A., & El-Abhar, H. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-90545-4 · Cited by 38
Novel mechanistic insights towards the repositioning of alogliptin in Parkinson's disease
Safar, M. M., Abdelkader, N. F., Ramadan, E. S., Kortam, M. A., & Mohamed, A. F. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120132 · Cited by 38
Jia, Y., Gong, N., Li, T., Zhu, B., & Wang, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.008 · Cited by 38
Self-citationImpact of glucose-lowering therapies on risk of stroke in type 2 diabetes
Bonnet, F., & Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.04.004 · Cited by 38
Sharma, S., & Taliyan, R. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.025 · Cited by 38
Disease-Modifying Drugs in Parkinson’s Disease
Park, A., & Stacy, M. A. (2015) · Drugs · doi:10.1007/s40265-015-0497-4 · Cited by 37
Abdelwahed, O. M., Tork, O. M., el Din, M. G., Rashed, L. A., & Zickri, M. B. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.02.002 · Cited by 37
Novel Targets for Parkinson’s Disease: Addressing Different Therapeutic Paradigms and Conundrums
Rane, P., Sarmah, D., Bhute, S., Kaur, H., Goswami, A., Kalia, K., Borah, A., Dave, K. R., Sharma, N., & Bhattacharya, P. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00180 · Cited by 37
Wang, V., Kuo, T., Huang, E. Y., Ma, K., Chou, Y., Fu, Z.-Y., Lai, L.-W., Jung, J. H., Choi, H.-I., Choi, D., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00013 · Cited by 37
Self-citationShandilya, A., & Mehan, S. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05328-6 · Cited by 37
Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes
Bak, A. M., Egefjord, L., Gejl, M., Steffensen, C., Stecher, C. W., Smidt, K., Brock, B., & Rungby, J. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.600691 · Cited by 36
“Futhermore, it has been demonstrated that exendin-4 can reduce brain damage and improve functional outcome in a transient middle cerebral artery occlusion stroke model [53].”
BackgroundPotential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders
McDonald, T. S., Lerskiatiphanich, T., Woodruff, T. M., McCombe, P., & Lee, J. D. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221135061 · Cited by 36
“In mesencephalic and SH-SY5Y neuronal cell cultures, known to be rich in dopaminergic neurons, exendin-4 protected dopaminergic cells from 6-OHDA damage.(138) Thus, as in AD, it seems that insulin resistance contributes to disease progression and neuronal loss in PD (Figure 2).”
BackgroundHan, W., Li, Y., Cheng, J., Zhang, J., Chen, D., Fang, M., Xiang, G., Wu, Y., Zhang, H., Xu, K., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15501 · Cited by 36
Self-citationPotential Crosstalk Between Parkinson's Disease and Energy Metabolism
Liu, M., Jiao, Q., Du, X., Bi, M., Chen, X., & Jiang, H. F. (2021) · Aging and Disease · doi:10.14336/ad.2021.0422 · Cited by 36
“These analogs could diminish α-Syn expression and oxidative stress levels in DAergic neurons, increase TH levels in primary DAergic neurons, and improve motor symptoms in rodent models of PD [56].”
BackgroundPiątkowska‐Chmiel, I., Gawrońska‐Grzywacz, M., Popiołek, Ł. P., Herbet, M., & Dudka, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-10187-y · Cited by 36
Metadata
- Authors
- Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., Brossi, A., Lahiri, D. K., Mattson, M. P., Hoffer, B. J., Wang, Y., & Greig, N. H.
- Affiliations
- National Institute on Aging (US)
- Medical University of South Carolina (US)
- National Institute on Drug Abuse (US)
- University of North Carolina at Chapel Hill (US)
- Indiana University School of Medicine (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-01-27
- Volume
- 106
- Issue
- 4
- Pages
- 1285-1290
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2633544
- OpenAlex
- W2080785707
- Cited by
- 589
- References
- 45
- Citations by year
- 2026: 18 · 2025: 39 · 2024: 39 · 2023: 24 · 2022: 33 · 2021: 49 · 2020: 41 · 2019: 40 · 2018: 43 · 2017: 34 · 2016: 41 · 2015: 45 · 2014: 34 · 2013: 33 · 2012: 27
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- University of Toronto
- National Institutes of Health
- National Institute on Aging
- National Institute on Drug Abuse
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- GLP-1 receptor, exendin-4, stroke, Parkinson's disease, dopaminergic neurons, cortical neurons, neuroprotection, MPTP mouse model, middle cerebral artery occlusion, 6-hydroxydopamine, hypoxia, oxidative stress, dopamine levels, motor function
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Cells, Cultured, Cerebral Cortex, Disease Models, Animal, Dopamine, Embryo, Mammalian, Gene Expression Regulation, Humans, Mesencephalon, Neurons, Parkinson Disease, Peptides, Venoms, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Cell Hypoxia, Treatment Outcome, Cell Death, Receptors, Glucagon, Cytoprotection, Brain Infarction, Stroke, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.